In addition to its well-characterized role in the central nervous system, human glutamate carboxypeptidase II (GCPII; Uniprot ID Q04609) acts as a folate hydrolase in the small intestine, participating in the absorption of dietary polyglutamylated folates (folyl-n-c-L-glutamic acid), which are the provitamin form of folic acid (also known as vitamin B 9 ). Despite the role of GCPII as a folate hydrolase, nothing is known about the processing of polyglutamylated folates by GCPII at the structural or enzymological level. Moreover, many epidemiologic studies on the relationship of the naturally occurring His475Tyr polymorphism to folic acid status suggest that this polymorphism may be associated with several pathologies linked to impaired folate metabolism. In the present study, we report: (a) a series X-ray structures of complexes between a catalytically inactive GCPII mutant (Glu424Ala) and a panel of naturally occurring polyglutamylated folates; (b) the X-ray structure of the His475Tyr variant at a resolution of 1.83 A; (c) the study of the recently identified arenebinding site of GCPII through mutagenesis (Arg463Leu, Arg511Leu and Trp541Ala), inhibitor binding and enzyme kinetics with polyglutamylated folates as substrates; and (d) a comparison of the thermal stabilities and folate-hydrolyzing activities of GCPII wild-type and His475Tyr variants. As a result, the crystallographic data reveal considerable details about the binding mode of polyglutamylated folates to GCPII, especially the engagement of the arene binding site in recognizing the folic acid moiety. Additionally, the combined structural and kinetic data suggest that GCPII wild-type and His475Tyr variant are functionally identical.
Introduction
Glutamate carboxypeptidase II (GCPII; EC 3.4.17.21) is a 750 amino acid type II transmembrane glycoprotein [1] and a Zn 2+ -dependent metalloprotease of the M28 peptidase family (Fig. 1 ). This enzyme is also known as prostate-specific membrane antigen, folate hydrolase 1, folyl-poly-c-glutamate carboxypeptidase and N-acetylated-a-linked acidic dipeptidase. These different designations reflect the various functions and tissue distribution of this protein.
The well-known and thoroughly studied enzymatic activity of GCPII is the cleavage of peptide neurotransmitter N-acetyl-L-aspartyl-L-glutamate (NAAG) into N-acetyl-L-aspartate and L-glutamate [2] [3] [4] [5] [6] . By contrast, nothing is known about the folyl-poly-c-Lglutamate hydrolyzing activity of GCPII. At the lumenal surface of the human jejunum, GCPII cleaves clinked L-glutamates from folyl-poly-c-L-glutamic acids (FolGlu n ) [7] , the storage form of folic acid that cannot pass through the cell membrane [8] . (Structures of the folyl-poly-c-L-glutamic acids and their building block pteroic acid, which is composed of a substituted pteridine double-ring and p-aminobenzoyl moiety, are shown in Fig. 1 ) Atlhough the structural and enzymological aspects of FolGlu n cleavage have not been characterized and folate is crucial for replication of rapidly dividing cells, the physiological relevance and Fig. 1 . Overall view of GCPII topology with the active site, ABS, His475Tyr mutation, and natural substrates NAAG and folyl-poly-c-Lglutamates (FolGlu n ) highlighted. Note that folic acid (abbreviated as FolGlu 0 ) is pteroic acid linked to a single glutamate residue with a peptide bond. Mono-c-L-glutamylated folic acid is abbreviated FolGlu 1 . Pteroic acid is composed of a substituted pteridine moiety linked to paminobenzoic acid via a nitrogen atom. The left monomer of GCPII is shown in surface representation, with saccharide moieties depicted as gray spheres, the protease domain (amino acids 57-116 and 352-590) in red, the apical domain (amino acids 117-351) in green and the Cterminal domain (amino acids 591-750) in blue. The right monomer is shown in cartoon representation, with the ABS highlighted in the upper circle and the surface amino acid His475, subject of the disputed polymorphism, in the lower circle.
structural and enzymological aspects of FolGlu n cleavage in the small intestine have not been well-characterized. Numerous reports and epidemiologic studies on the naturally occurring His475Tyr polymorphism have analyzed the potential influence of this polymorphism on physiological levels of folates and folate-related metabolites (e.g. homocysteine). Some studies involving 600-1900 subjects concluded that this polymorphism influences neither folate, nor homocysteine levels [9] [10] [11] . By contrast, a study including 2700 subjects concluded that the His475Tyr polymorphism confers higher folate and lower homocysteine levels [8] .
Other much smaller studies (30-44 participants) have correlated the polymorphism with altered folate levels and some pathologies, such as breast cancer [12] . Importantly, all of these studies investigated only genotype-phenotype association data, which makes their results rather inconclusive. For these reasons, the folyl poly-c-L-glutamate hydrolyzing activity of GCPII and its natural His475Tyr variant, both at the structural and enzymological level, is the focus of the present study.
Structurally, the extracellular part of GCPII folds into three distinct domains: the protease domain (amino acids 57-116 and 352-590), the apical domain (amino acids 117-351) and the C-terminal domain (also called the dimerization domain; amino acids 591-750) (Fig. 1) . All three GCPII domains contribute to formation of the substrate binding cavity, which consists of the S1 site, the active site and the S1 0 site. The active site features two Zn ions coordinated by the side chains of His377, Asp387, Asp453, Glu425 and His553. In the vicinity of the S1 site, there is a highly flexible segment called the 'entrance lid' (amino acids Trp541 to Gly548). In its closed conformation, the entrance lid fully shields the substrate binding cavity from the extramolecular space, as observed when small substrates such as NAAG are bound [4] [Protein Data Bank (PDB) code: 3BXM]. When the entrance lid is in open conformation, larger inhibitors can bind [13] (PDB code: 2XEF, 2XEG, 2XEI, 2XEJ). Similar to the S1 site, the S1 0 site can be shielded from the extramolecular space by a flexible amino acid segment. The so-called 'glutarate-sensor' (Tyr692 to Ser704) takes on a b-stranded conformation upon binding of the glutamic acid moiety in the S1 0 position, sealing off an otherwise present small funnel [6, 14] .
Recently, Zhang et al. [13] identified and structurally characterized an exosite of GCPII that binds aromatic moieties. This exosite, termed the arene-binding site (ABS), is formed by the first amino acid of the entrance lid, Trp541, together with Arg511 and Arg463. Adding a dinitrophenyl moiety with a length-optimized linker to a GCPII inhibitor significantly enhances the inhibitor's affinity toward GCPII via the avidity effect (i.e. by allowing it to bind to GCPII in a bidentate mode).
The present study aimed to determine: (a) how GCPII recognizes and cleaves polyglutamylated folates; (b) the role of the ABS in the recognition and binding of folyl-poly-c-L-glutamic acids; and (c) whether the His475Tyr polymorphism alters the hydrolyzing activity of folyl-poly-c-L-glutamate. Accordingly, we solved a series of X-ray structures of complexes between the inactive GCPII mutant, Glu424Ala, and several naturally occurring polyglutamylated folates (FolGlu [1] [2] [3] [4] [5] [6] ). In addition, we analyzed the three-dimensional (3D) structure of the GCPII His475Tyr variant and compared its activity with the wild-type using a novel assay, and also performed structure-activity studies of the ABS.
Results
X-ray structures of recombinant human GCPIIGlu424Ala-FolGlu 1/2/3/4/5/6 complexes To shed light on the binding mode of individual polyglutamylated folates in the substrate-binding pocket of GCPII, we determined X-ray structures of seven complexes of the hydrolytically inactive recombinant human GCPII (rhGCPII) Glu424Ala mutant [4] and FolGlu 1/2/3/4/5/6 substrates. The FolGlu 1-3 structures were refined at resolutions of between 1.65 and 2.00 A, with good crystallographic parameters ( Table 1) . Their overall folds are almost identical. The only major differences were observed in the conformation of residues Arg463, Arg511 and Trp541 (forming the ABS) implicated in substrate binding. For FolGlu 1-2 , the complete substrate molecules were defined in the electron density. For FolGlu 3 , only the C-terminal di-c-L-glutamyl-glutamate and pteridine moieties were defined in the electron density map ( Fig. 2A) . In the structures obtained using FolGlu 0/4/5/6 crystallization conditions, only di-c-L-glutamyl-glutamate moieties could be modeled, and the remaining parts of these substrates were not defined in the electron density (data not shown).
As expected, the ultimate (C-terminal) glutamate, the scissile peptide bond and the penultimate (S1-bound) glutamate overlap in all seven structures (data not shown). The C-terminal glutamate is placed in the S1 0 pocket in a manner identical to that described for previously reported structures [13, 15] , as indicated, for example, by the superposition of FolGlu 1-3 structures with the ARM-P4 structure (Fig. 2B) . The carbonyl oxygen of the scissile peptide bond is polarized by the Zn1 ion (2.5 A; not visible in Fig. 2B ) and the polarization/positioning is further assisted by its interactions with the Tyr552 hydroxyl group (2.7 A) and His553 Ne2 (3.1 A). The peptide amide group donates a hydrogen bond to the main-chain carbonyl oxygen of Gly518 (3.0 A). The a-carboxylate of the penultimate glutamate directly engages positively charged Arg534 (2.6 A) and Arg536 (3.1 A). The above-mentioned interactions are structurally conserved for both folate-based and NAAG substrates [4] .
More structural diversity was observed for the distal (pteroate) parts of individual substrates. In the case of FolGlu 1 ( Fig. 2A) , the 'single glutamate linker' is too short for the benzoate/pteroate moieties to reach fully into the ABS. Instead, the p-amino benzoyl moiety of FolGlu 1 is engaged in a staggered p-p stacking interaction with the S1 0 and S1 side chain of Tyr700 (3.7 A) ( Fig. 2C) , whereas the pteridine ring system interacts in a p-cation fashion with the side chain of Arg463 ( Fig. 2A) . Another consequence of the substrate being too short is that the electron desity map allows the Trp541 to be modeled in only one conformation (whereas, for FolGlu 2-3 complexes, two conformations are possible). The Trp541 residue is in a conformation of p-p stacking with the pteroate moiety. For Substrates are in stick representation; selected GCPII residues are shown as lines. Note the flexibility of the ABS residues (Arg463, Arg511 and Trp541), which is crucial for engagement of the distal pteroate moiety of the substrates by GCPII, whereas the S1 site residues (Arg 534, Arg536, Tyr700) take up almost the same conformation in both structures. The active-site zinc atoms are shown as purple spheres; selected hydrogen bonds are shown as broken lines.
( Fig. 2A ), which features a one-Glu-residue-longer linker, p-cation and T-shaped stacking interactions were observed between the p-aminobenzoyl group of the substrate and side chains Arg463 (3.3 A) and Trp541 (3.2 A), respectively (Fig. 2C ). The pteridine ring is wedged between the side chains of Arg511 and Trp541 with its plane parallel to the indole of Trp541 (3.3 A) and the guanidinium group of Arg511 (3.3 A). We observed two possible conformations for Trp541, as well as higher B-factors for its side chain. A simple overlay of FolGlu 1 and FolGlu 2 structures is provided in Fig. 2C , with amino acids of the ABS (Arg463, Arg511, Trp541) and the S1 site (Arg 534, Arg536, Tyr700) shown as lines. This overlay illustrates that the S1 site residues (Arg 534, Arg536 and Tyr700) are essentially in the same conformation (except for a double conformation of Arg536 in the FolGlu 1 structure), whereas the ABS residues (Arg463, Arg511, Trp541) adopt different conformations according to the length of the c-glutamyl chain of the folic acid. For FolGlu 3 ( Fig. 2A) , the binding mode and positioning of the pteroate moiety are almost identical to those observed for FolGlu 2, with Trp541 present in two conformations. However, the 2F o À F c electron density for the distal parts of FolGlu 3 was much weaker, and the Bfactors of the final model were much higher compared to those calculated for the structure of the FolGlu 2 complex. As already noted above, FolGlu 3 substrate has only the C-terminal di-c-L-glutamyl-glutamate and pteridine moieties defined in the electron density map, and so the p-aminobenzoic acid moiety and the most distal glutamic acid residue are modeled rather only sterically. These factors highlight the conformational flexibility of FolGlu 3 and the limited contribution of its distal part to GCPII binding. In general, the side chain of Trp541 was defined by a weak 2F o À F c electron density in our structures ( Fig. 2A ) and the variety of conformations observed indicates the inherent flexibility of this residue. In summary, the structures of FolGlu [1] [2] [3] [4] [5] [6] complexes reported in the present study clearly suggest that His475 is a surface residue too distant from the binding cavity and cannot play a role in the interaction of GCPII with folyl-poly-c-L-glutamic acids.
Structural characterization of recombinant human GCPII His475Tyr
To determine the putative effects of the His475Tyr substitution on the 3D structure of GCPII and on the enzyme's substrate binding and processing, we co-crystallized the rhGCPII His475Tyr variant with the natural substrate NAAG. Similar to our previous observations [3] for the wild-type enzyme, glutamate (the product of the enzymatic reaction) was observed in the S1 0 site of the final model, which was refined at 1.83
A resolution, with crystallographic R-factors equal to 0.159 (R free = 0.191; for complete data collection and refinement statistics, see Table 1 ).
The His475Tyr/glutamate structure (PDB code: 4MCS) was analyzed and compared with the corresponding complex of glutamate with the wild-type enzyme [3] (PDB code: 2C6G). The overall fold is almost identical for both the His475Tyr and wild-type proteins, as illustrated by a r.m.s.d. of 0.19 A (for the 661 equivalent Ca pairs). Additionally, no differences were observed in the arrangement of the internal substrate-binding cavity and residues in the active site or in the positioning and binding mode of glutamate. Most importantly, both proteins share an almost identical arrangement of amino acids in the vicinity of residue 475, and the imidazole ring of wild-type His475 and the benzene ring of Tyr475 overlap spatially (Fig. 3) .
Site-directed mutagenesis study of the ABS
The structural data reported in the present study indicate that at least some FolGlu n substrates interact with GCPII in a bidentate mode: the C-terminal and penultimate glutamates engage residues of the S1 0 and S1 sites, respectively, whereas the pteridine double-ring and p-aminobenzoyl moiety interact with the residues of the recently identified ABS [13] . To investigate the role of the ABS in folate binding and hydrolysis, a series of GCPII variants with mutations in the ABS (Arg463Leu, Arg511Leu and Trp541Ala) was prepared by site-directed mutagenesis, expressed in Drosophila S2 cells, and purified to homogeneity. The activities of these enzymes were characterized in terms of their hydrolysis of NAAG and FolGlu 4 (substrates with structurally no and a poorly defined interaction with the ABS, respectively) and FolGlu 1-3 (substrates with structurally welldefined interactions of the pteridine double-ring with the ABS). We assumed that, if interactions between FolGlu 1-3 and the ABS influence the kinetic parameters of substrate hydrolysis, a decrease in substrate affinity (i.e. an increase in K M value) should be observed for the GCPII ABS mutants. Although no major differences between the three mutants and the wild-type enzyme were observed for the kinetic parameters of FolGlu 1 hydrolysis, there was a slight decrease in K M values for both NAAG and FolGlu [2] [3] [4] (Fig. 4) . However, because the binding of NAAG does not engage residues of the ABS [13] , the observed changes cannot be linked to the interaction of the pteroate with the ABS.
To analyze the relevance of the ABS for interactions with small molecule ligands, we compared the inhibition profiles of four GCPII-specific inhibitors [13] (Fig. 5) towards the Trp541Ala mutant and the wildtype enzyme. Three of these inhibitors (ARM-P2, ARM-P4 and ARM-P8; urea based inhibitors containing the ABS-targeted dinitrophenyl moiety linked via 2/4/8 ethyleneglycol units) have been reported to engage the ABS. On the other hand, the MeO-P4 compound (urea based inhibitor with four ethyleneglycol units containing no arene-binding site targeted moiety) is incapable of any interactions with ABS residues [13] .
The inhibition data are summarized in Fig. 5 . As expected, we observed no difference between the mutant and wild-type proteins in the K i values for MeO-P4. By contrast, two inhibitors featuring the distal dinitrophenyl moiety linked with an optimal linker (and thus capable of ABS interactions; ARM-P4, ARM-P8) demonstrate an affinity that was several-fold higher for the wild-type protein compared to Trp541Ala (Fig. 5B) , thus confirming the relevance of the ABS (namely Trp541) for the binding of aromatic moieties. Moreover, for ARM-P4, we observed an approximately one-order-of-magnitude difference in K i values for Trp541Ala and Arg463Leu compared to wild-type ( Fig. 5C ; for the structure of GCPII in complex with ARM-P4, see Fig. 2A ).
Enzymatic characterization of recombinant human GCPII wild-type and His475Tyr
A single study describes a~50% decrease in the folate-hydrolyzing activity of the His475Tyr variant compared to the wild-type enzyme [16] . To provide a detailed enzymatic characterization and side-by-side comparison of the wild-type and His475Tyr variants, we developed a novel UPLC-based assay and measured the kinetic parameters of hydrolysis of a panel of natural GCPII substrates by purified recombinant proteins (Fig. 6) 
Thermal stability of recombinant human GCPII wild-type and His475Tyr
Although the wild-type and His475Tyr variants are almost indistinguishable at the structural level, we investigated the possibility that the His to Tyr substitution influences the thermal stability of the His475Tyr variant. Accordingly, we used a Thermofluor assay to define the temperature midpoint for the unfolding transition, T m . The T m value determined for the wildtype protein (67.2 AE 0.118°C) is comparable to that determined for the His475Tyr variant (69.2 AE 0°C), in disagreement with a biologically significant (de)stabilization effect of the mutation. The kinetic parameters obtained for folate-based substrates, together with the data obtained by 3D structure analysis and thermal stability experiments, suggest that the His475Tyr variant is equivalent to the wild-type enzyme at both the structural and enzymological levels.
Discussion
The present study aimed to investigate the molecular recognition of polyglutamylated folates by GCPII and to clarify whether the reported His475Tyr polymorphism might alter the binding and/or turnover of polyglutamylated folates, potentially leading to altered levels of folates and related metabolites in humans. Furthermore, we set out to analyze the role of the ABS, a recently identified putative exosite in the GCPII structure, with respect to the molecular recognition of polyglutamylated folates and, more generally, in the binding of ligands containing an aromatic moiety capable of interacting with this exosite.
Although extensive epidemiologic studies on the effect of the His475Tyr polymorphism have been conducted, the possible role of this mutation in the folate uptake and metabolism of metabolically related molecules remains unclear. Folates are essential for the C1 metabolism of cells (i.e. for the biosynthesis of nucleobases) and they are important for the replication of rapidly dividing cancer cells. Folate insufficiency might result in altered levels of folate-related metabolites and/or in an altered susceptibility to certain types of cancer. However, it is difficult to speculate how a single amino acid mutation in a region distant from the active site ( Fig. 1; His475 is located 27 A from the active site Zn1) could influence the catalytic activity of the enzyme. Nevertheless, there have been reports of long-range rearrangements of an enzyme's substrate binding cleft caused by very distant mutations; for example, in HIV-1 protease [17] . Thus, the idea that the His475Tyr mutation could influence GCPII activity was worthy of consideration. However, we found that the enzymatic properties of recombinant human GCPII His475Tyr are very similar to those of the wild-type enzyme (almost identical K M values and turnover numbers toward all tested folyl-poly-c-L-glutamate substrates). Furthermore, 3D structure analysis of the protein by X-ray crystallography did not reveal any significant structural changes caused by the mutation. The very subtle differences that we observed cannot account for the reported phenotype of the polymorphism [8] [9] [10] [11] [12] .
It is relevant to note that all recombinant proteins discussed in the present study were prepared in Drosophila S2 cells and comprise the full ectodomain of human GCPII in which the enzymatic activity resides. We have previously shown that the enzymatic activity of this recombinant protein is indistinguishable from that of native, full-length GCPII [18] .
All seven structures solved as part of the present study provide structural explanation as to why the His475Tyr mutant behaves almost identically to the wild-type enzyme. Our structural analysis showed that the bound FolGlu 1-6 substrates do not interact with His475. Additionally, the structure of GCPII His475-Tyr exhibits no significant re-arrangement of the substrate binding pocket. Although the enzymologic comparison of rhGCPII wild-type and His475Tyr identified no significant differences in the cleavage of FolGlu n , thermal stability, or structure, the possibility remains that the His475Tyr mutation causes altered folic acid levels and folate-related metabolites in humans. The His475Tyr mutation may influence folate levels by other mechanisms (e.g. by changing the trafficking of GCPII, by changing its expression level or by changing the enzyme's interaction with potential signaling partners). These potential mechanisms of action remain to be investigated.
There was one peculiarity about the X-ray structure of the complex obtained from the crystallization condition with the inactive GCPII mutant (Glu424Ala) and FolGlu 0 . As already noted, this structure contains a di-c-L-glutamyl-glutamic moiety, even though no compound containing such a moiety has been added to the crystallization drop. A possible explanation is that some higher polyglutamylated folates (FolGlu >4 ) originating from the cultivation medium may have remained bound throughout the purification process (only a one-step affinity purification), not allowing the FolGlu 0 to bind. In line with such a hypothesis, folic acid did not inhibit the cleavage of FolGlu 3 (data not shown), suggesting that the folate (the product) has a lower affinity to the enzyme than polyglutamylated folate (the substrate).
Inspection of the kinetic properties of the wild-type and His475Tyr variants revealed that folate substrates harboring more than two C-terminal glutamates bound to the enzyme more effectively (by almost one order of magnitude), as reflected by differences in their K M values (compare FolGlu 1 and FolGlu 2-6 ; Fig. 6A ). This difference in K M is in good agreement with the previously published observation that the di-c-L-glutamate moiety inhibited the NAAG-hydrolyzing activity of GCPII twenty-fold less effectively than the tri-c-L-glutamate moiety, whereas tri-, tetra-and penta-c-L-glutamate moieties were observed to inhibit to a similar extent [19] .
To further analyze the contribution of the ABS to substrate recognition, we performed site-directed mutagenesis of the key residues of the exosite (Arg463, Arg511 and Trp541). Kinetic analysis of the recombinant mutant proteins did not show a major influence of the ABS residues on polyglutamyl-folate binding and turnover, and only a modest, approximately three-fold increase in NAAG binding affinity. Because NAAG cannot engage the ABS, the direct effects of these mutations on substrate recognition can be excluded and more intricate/subtle (unidentified) contributions (e.g. the flexibility of the entrance lid) may play a role.
The binding of selected inhibitors targeting the ABS, on the other hand, was shown to be influenced by their interaction with the residues forming the ABS both structurally and by using inhibition studies [13] . The present study tested those inhibitors with rhGCPII wild-type and Trp541Ala variants [13] (structures of the inhibitors are shown in Fig. 5A ). Inhibitors that had been previously reported to interact with the ABS showed a significant loss of binding to the GCPII Trp541Ala variant, in which the ABS is presumably disrupted (Fig. 5B) , confirming the importance of this structural feature for inhibitor binding. It is somewhat unexpected that, on the one hand, the crystallographic and site-directed mutagenesis data of the ABS provide a good mechanistic explanation for changes in inhibitor affinity, whereas, on the other hand, there is a disconnection between the structural data (ABS engages the pteroate) and kinetic studies (mutations in the ABS mostly do not change the kinetic parameters of substrate hydrolysis). We can speculate that these differences might be attributed to differences in the kinetics of substrate versus inhibitor interactions with GCPII. The crystallographic data represent the most preferred conformation of a given GCPII complex achieved in a time-scale of several days (crystal growth). In addition, when a typical inhibition constant is determined, the inhibitor is usually preincubated with the enzyme for several minutes (5-13 min in this case), giving the inhibitor sufficient time to adopt the most energetically favorable conformation. On the other hand, a k cat > 1 s À1 indicated that a given substrate is bound and hydrolyzed in less than a second. Although the high-affinity C-terminal part of the substrate is docked into (and released from) the active site of GCPII within this time scale, the flexible distal part might not be able to engage the ABS and thus has limited (or no) contribution to the overall affinity. This conjecture is supported by binding kinetics observed for GCPII interactions with a fluorescently labeled GCPII inhibitor/probe [20] . We have observed that the BODIPY fluorophore engages the ABS (C. Ba rinka, unpublished work) and that this engagement leads to quenching of fluorescence intensity. The fluorescence quenching is rather gradual, taking tens of seconds, rather than being instantaneous. This suggests a bidentate mode of substrate/inhibitor binding, in which the C-terminal (docking) part of the inhibitor binds 'immediately' and the distal part binds somewhat more slowly. Another possibility could be that this exosite is inherently a lower-affinity site allowing the binding of all forms of folic acid moiety (folyl/5-methyl-dihydrofolyl/5-methyltetrahydrofolyl). The natural diet contains predominantly 5-methyl-tetrahydrofolyl-poly-c-L-glutamates [21] , which are less stable than their fully oxidized folylforms and may easily be oxidized to 5-methyl-dihydrofolyl-poly-c-L-glutamates or may even degrade to the folyl-forms. The same may apply to the folate receptor a isoform, which has been recently co-crystallized with the folic acid but not with 5-methyl-tetrahydrofolic acid [22] (PDB code: 4LRH), although this isoform of folate receptor is expressed in kidney in renal tubular cells to resorb 5-methyl-tetrahydrofolic acid, a major form of folic acid found in blood.
Another indication that the ABS is a rather lowaffinity binding site is provided by the x-ray structure of GCPII in complex with a nonhydrolyzable methotrexate analogue of the FolGlu 1 substrate (PDB code: 3BI1) [23] . In this structure, only the c-D-glutamyl-Lglutamate moiety with a spatial arrangement analogous to that seen in FolGlu 1-3 structures was defined by the electron density map, whereas the pteridine ring was disordered and no stacking with Trp541 could be observed [23] .
Measurements of kinetic parameters also revealed that the mechanism by which polyglutamylated folates are cleaved is probably distributive (i.e. the c-linked Lglutamates from folyl-poly-c-L-glutamic acids are cleaved sequentially from the C-terminus). For higher FolGlu n turnovers (10-20%), we have always observed a small amount (~1-2%) of the FolGlu n-2 product (data not shown; the contribution of the FolGlu n-2 product to the kinetic data could thus be neglected).
The data reported in the present study might be a starting point for the design of a homolog-specific ligand or inhibitor of GCPII and GCPIII. Although these two homologous proteins share 81% similarity at the amino acid sequence level [24] and their 3D structures are very similar [25] , some studies suggest that GCPIII might play a distinct enzymatic role in specific tissues, such as the testes [26] . As shown by Zhang et al. [13] , the choice of a proper ABS-targeting moiety can improve inhibitor potency by several orders of magnitude. Because GCPIII does not appear to have a corresponding ABS in its structure, an appropriate inhibitor targeting this exosite in GCPII might represent a useful tool for distinguishing both enzymes at the protein level.
Materials and methods

Preparation of rhGCPII
rhGCPII wild-type and mutants were heterologously overexpressed in Drosophila Schneider 2 (S2) cells [27] using the pMT/Bip/AviTEV/rhGCPII vector, as described previously [28] . In this expression system, the soluble extracellular part of GCPII N-terminally fused with a so-called AviTEV tag is secreted into the medium. The AviTEV tag comprises an in vivo biotinylated Bir ligase recognition sequence (AviTag TM ; Avidity, Aurora, CO, USA) separated from the target protein with a tobacco etch virus (TEV) recognition sequence. Proteins were purified using the Streptavidin Mutein Matrix TM (Roche Diagnostics, Basel, Switzerland) [28] .
Site-directed mutagenesis and cloning
The Glu424Ala and His475Tyr mutations were introduced by cutting the coding sequence out of the corresponding pMTNAEXST vector [4] using the restriction enzymes BglII/XhoI (New England Biolabs, Ipswitch, MA, USA) and XhoI/XcmI (New England Biolabs), respectively, and religating into the pMT/Bip/AviTEV/rhGCPII vector using T4 DNA ligase (New England Biolabs). The mutations Arg463Leu, Arg511Leu and Trp541Ala were introduced by mutating the pMT/Bip/AviTEV/rhGCPII vector using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). Nucleotide sequences (5 0 to 3 0 ) of the primers were: GAAGGAAACTACACTCTGTTAGTTGATT GTACACCGCTGATG (forward primer, Arg463Leu), CATCAGCGGTGTACAATCAACTAACAGAGTGTAG TTTCCTTC (reverse primer, Arg463Leu), GTTCAGT GGCATGCCCCTGATAAGCAAATTG (forward primer, Arg511Leu), CAATTTGCTTATCAGGGGCATGCCACT GAAC (reverse primer, Arg511Leu), GTATACTAAA AATGCCGAAACAAACAAATTCAG (forward primer, Trp541Ala) and CTGAATTTGTTTGTTTCGGCATTT TTAGTATAC (reverse primer, Trp541Ala). Before synthesis, all primer sequences were checked using OLIGOCALC [29] . Sequences of the resulting plasmids were verified by dideoxynucleotide termination sequencing. Yields of pure recombinant proteins were 0.63 mgÁ100 mL À1 of media for the wild-type enzyme [28] , 83 lgÁ100 mL À1 for His475Tyr, 9.5 lgÁ100 mL À1 for Arg463Leu, 6.3 lgÁ100 mL À1 for Arg511Leu and 0.10 mgÁ100 mL À1 for Trp541Ala.
Crystallization and data collection
Crystals were grown by the hanging drop vaporization technique at 291 K, as described previously [30] , A; MX-225; the His475Tyr variant and complexes with FolGlu 2/5/6 ). Complete datasets were collected from single crystals, and data were processed using either HKL2000 [31] or XDSAPP [32] . The complex with FolGlu 2 was tested in-house at 120 K on the MAR345 detector (MAR Research, Hamburg, Germany) using Cu Ka wavelength (1.5418 A).
Structure determination and refinement
Structures of GCPII Glu424Ala complexes were determined by molecular replacement method using the coordinates of the GCPII-Glu424Ala-NAAG complex (PDB code: 3BXM) as a starting model [4] . Refinement calculations and manual rebuilding were performed with REFMAC, version 5.5 [33] and COOT, version 6.1 [34] , respectively. Approximately 1.0-1.7% of the data (corresponding to 1140-1736 reflections) were excluded from calculations and used instead to calculate the R free value (R free sets were independent). Models for individual substrates together with associated restraints were prepared using the PRODRG server [35] and were placed into the positive F o À F c electron density maps, located in the substrate binding cavity of rhGCPII. An isotropic refinement protocol was used throughout all stages of the refinement. The stereochemical quality of the final models was evaluated using MOLPROBITY [36] . Data collection and structural refinement statistics are shown in Table 1 .
GCPII activity assay
Reactions with the folyl-(1/2/3/4/5/6)-c-L-glutamic acid substrates (Schircks Laboratories) and NAAG (Sigma-Aldrich) were performed in 25 mM Tris-HCl (pH 7.5) in a total volume of 250 lL. Concentrations of substrate stock solutions were determined by amino acid analysis. All components were pipetted at 0°C, and reactions were started by adding enzyme and mixing. The reactions were placed in a 37°C thermo-block (MB-102, Bioer, Hangzhou, China, or Thermomixer Comfort, Eppendorf, Hamburg, Germany) for 20 min. These reaction conditions were designed to yield 10-20% conversion of substrate. Reactions were stopped by adding 3.5 lL of stopping solution [72 lM 2-(phosphonomethyl)-pentanedioic acid (2-PMPA), 7.2 mM 2-mercaptoethanol (Sigma-Aldrich), 25 mM Tris, 0.48 M phosphoric acid (Penta, Praha, Czech Republic)]. Typically, nine data points were plotted for each substrate (with each point representing the mean of duplicate experiments) and saturation curves were fitted using GRAFIT [37] . For inhibition and kinetic studies with FolGlu 1-6 as a substrate, reactions were performed in 25 mM bistrispropane-HCl (Sigma-Aldrich) (pH 7.5). Reactions were carried out either in a total volume of 215 lL in a 96-well plate immersed in a water bath (Grant Instruments, Shepreth, UK) or in a total volume of 250 lL in 1.5-mL test tubes in a thermo-block (MB-102). All components except the substrate were pipetted at 0°C. After a 5-13 min of preincubation at 37.0°C (5 min of preincubation in the case of the 1.5-mL test tubes), substrate was added. The reaction proceeded for 20 min and was terminated by the addition of 10.0 lL of stopping solution [0.44 M phosphoric acid and 21.3 lM 2-PMPA (96-well plate) or 3.48 lL of 1.5 M phosphoric acid and 71.3 lM 2-PMPA (1.5-mL test tubes)]. The identity of the inhibitors was verified by Q-TOF Micro (Waters, Milford, MA, USA) and LTQ Orbitrap XL (Thermo Fisher Scientific, Waltham, MA, USA). Each inhibition curve was fitted using GRAFIT [37] into at least 12 data points typically acquired in duplicate.
Novel UPLC method for assaying glutamate carboxypeptidase activity using folyl-(1/2/3/4/5/ 6)-c-L-glutamic acids as substrates FolGlu n reaction mixtures were analyzed on a C18 Acquity UPLC HSS T3 2.1 x 100 mm column with 1.8-lm particles (Waters), guarded by a 0.22-lm pre-filter (Waters) and VanGuard pre-column (Waters), coupled to an Agilent 1200 Series UPLC instrument (Agilent Technologies, Santa Clara, CA, USA). Mobile phase A was 25 mM sodium phosphate buffer (pH 6.0) (Penta), supplemented with 0.02% (w/v) sodium azide (Sigma-Aldrich); mobile phase B was acetonitrile (VWR International, Radnor, PA, USA). Elution of individual FolGlu 1/2/3/4/5/6 molecules and their cleavage products was performed isocratically at 2.0%/ 1.5%/1.1%/0.4%/0.2%/0.0% acetonitrile, respectively. The column temperature was set to 50.0°C. The HPLC runs consisted of 1.8 min of isocratic flow at 0.0-2.0% B, 0.1 min of transition to 10.0% B, 1.1 min at 10.0% B, 0.1 min of transition back to 0.0-2.0% B and 7.4 min of re-equilibration. Analytes were detected at 281 nm and 354 nm. Inhibition reactions with FolGlu 1 were analyzed in the same manner, except that the percentage of acetonitrile was 2.1% instead of 2.0%. The substrate turnover was quantified as the ratio of the substrate and product peak areas. The sum of the areas of the substrate and the product served as an internal standard. The limit of quantification was at least 10 nM (when calculated as the baseline height multiplied by 10).
Novel UPLC method for assaying glutamate carboxypeptidase activity using NAAG as a substrate
The NAAG reaction mixtures were lyophilized for at least 6 h at 20 lbar using Beta 2-8 (LD plus, Christ, Osterode am Harz, Germany) or Labconco catalog number 7753511 (Labconco Instruments Kansas City, MO, USA) and re-dissolved in 25.0 lL of MilliQ water (Merck Millipore, Billerica, MA, USA). Then, surpassing the need for a radioactivelly labeled substrate traditionally used when assessing the NAAG hydrolysing activity of GCPII [2] , a modified fully automated orthophthalaldehyde-derivatization [38] step was performed: 11.0 lL of each re-dissolved reaction was manually transferred into a 96-well plate, and the plate was inserted into an autosampler set to 4°C. A 99.0-lL aliquot of the derivatization solution [40.6 mM 2-mercaptopropionic acid (SigmaAldrich), 33.0 mM ortho-phthalaldehyde (Sigma-Aldrich) in 200 mM sodium borate (Pharmacia, Uppsala, Sweden), pH 10.0] was added by the autosampler. After mixing, the sample was injected onto a C18 Acquity UPLC HSS T3 2.1 x 100 mm column with 1.8-lm particles (Waters), guarded by a 0.22-lm pre-filter (Waters) and VanGuard precolumn (Waters), coupled to an Agilent 1200 Series UPLC instrument (Agilent Technologies). Ortho-phthalaldehyde-Glu derivative was eluted isocratically with 96.0% mobile phase A [25 mM sodium phosphate buffer, pH 6.0 (Penta), supplemented with 0.02% (w/v) sodium azide (Sigma-Aldrich)] and 4.0% mobile phase B (acetonitrile). The column temperature was 70.0°C. The method consisted of 2.7 min of isocratic flow at 4.0% B, 0.1 min of transition to 80.0% B, 4.7 min at 80.0% B, 0.1 min of transition back to 4.0% B and 8.4 min of re-equilibration. Glutamate eluted after~1.4 min. Analytes were detected by fluorescence at 230/450 nm. The substrate turnover was quantified as the ratio of the peak areas of the glutamic acid (product) and the total cleavage reaction. The limit of quantification was estimated as x B + 10r B (mean of the blank measurement plus 10 9 SD of the blank) and was usually in the range 20-30 nM.
Thermofluor assay
To determine the temperature midpoint for the protein unfolding transition, T m , a thermal shift assay using SY-PRO Ò Orange (Invitrogen, Carlsbad, CA, USA) dye [39] was performed on a Roche LightCycler 
